Investor Presentaiton
Hematology
Reblozyl BET Inhibitor Breyanzi golcadomide Abecma
alnuctamab
GPRC5D
iber/mezi
Alnuctamab demonstrates deep and durable responses
in RRMM
Response, %
Overall Response Rate: Efficacy
supports the optimal Phase 3 dose¹
100
80
50
60
40
40
20
20
0
ORR = 41%2
14
■SCR
■CR
VGPR
ORR = 65%
PR
19
38
14
7
7
8
<30-mg target dose 30-mg target dose
(n=29)
(n=26)
Deep and durable responses with clinically
important MRD negativity1
Patients who achieved a response (n=29)
Safety¹
86% of responses ongoing and mDOR not reached
Grade ≥3
n=73
CRS
0
ICANS
0
SCR
CR
MRD neg (10-6)
MRD neg (10-5)
Infections
10%
VGPR
PR
PD
Ongoing
▲ Death
Hematologic:
Neutropenia
42%
Anemia
25%
•
Thrombocytopenia 14%
T
T
T
T
T
T
T
1
2
3
4
5
6
7
8
9 10 11 12 13
14 15 16
Time (months)
Responses deepened over time, with CRS limited to low-grade, short-lived events (median duration 2 days)
Ill Bristol Myers Squibb™
1. Wong SW, et al. EHA 2023 [Poster #P883]. 2. Values do not add to 41% due to rounding.
Not for Product Promotional Use
85View entire presentation